Urolithin A Research Library
Primary human trials and official product sources used to keep our buyer pages anchored to evidence rather than decorative mitochondrial vocabulary.
Human clinical research
Official product sources used for comparison pages
Why primary research matters
Primary studies and high-quality systematic reviews are more useful than repeating claims across supplement blogs.
How evidence is prioritized
Human randomized trials and systematic reviews carry more weight for outcome claims than cell or animal research.
How trials are interpreted
Participant characteristics, sample size, dose, duration, comparator, primary outcomes, adverse events, and funding all affect what can reasonably be concluded.
Ingredient versus finished-product evidence
A commercial product should not automatically inherit every finding associated with a named ingredient.
Null findings matter
Negative or null results should not be hidden because they weaken a marketing story.
Updates
New trials can change the strength of a conclusion, so research pages should remain revisable.
Funding and conflicts
Industry funding is relevant context but should not be used as a shortcut for either accepting or dismissing a study.
How readers should use the library
The research library is most useful for identifying what is known, what remains uncertain, and where commercial claims extend beyond the evidence.
Update trigger 1
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 2
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 3
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 4
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 5
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 6
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 7
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 8
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 9
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 10
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 11
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 12
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 13
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 14
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 15
For Urolithin A Research Library, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.